Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients

Annals of Oncology

Volumn 8, Issue 10, 1997, Pages 963-968

  Eisenhauer, E A ^a   Vermorken, J B ^b,c   Van Glabbeke, M ^d  

^a QUEEN S UNIVERSITY   (Canada)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c EORTC   (Belgium)

^d EORTC DATA CENTER   (Belgium)

Author keywords

Ovarian cancer; Predictive factors; Response; Second line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; EPIRUBICIN; GEMCITABINE; IRINOTECAN; PACLITAXEL; PLATINUM;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

FEMALE; HUMANS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROGNOSIS; REGRESSION ANALYSIS; RETREATMENT;

EID: 0030698757     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008240421028     Document Type: Article

References (12)

1. Van der Burg MEL, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332: 629-34.
2. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
3. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59: 650-3.
4. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207-11.
5. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93.
6. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton K et al. European-Canadian randomized trial of Taxol in relapsed ovarian cancer: High vs. low dose and long vs. short infusion. J Clin Oncol 1994; 12: 2654-66.
7. Vermorken JB, Kobierska A, Chevallier B et al. for the EORTC Gyn Cancer Coop Group. Phase II study of high-dose epirubicin (HDE) in ovarian cancer (OC) patients previously treated with cisplatin (P). Ann Oncol 1994; 5 (Suppl 5): 143 (Abstr 283).
8. Piccart MJ, Gore M, ten Bokkel Huinink W et al. Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87: 676-81.
9. Aapro MS, Pujade-Lauraine E, Lhomme C et al. EORTC Clinical Screening Group: Phase II study of Taxotere® in ovarian cancer. Ann Oncol 1994; 5 (Suppl 5): 202 (Abstr 508).
10. Bristol-Myers Squibb Co. Carboplatin database on file from 6 phase II trials.
11. Eli-Lilly Co. Gemcitabine database on file from 4 phase II trials.
12. Takeuchi S, Dobashi K, Fujimoto S et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Gan Kagaku Ryoho 1991; 18: 1681-9.